DNA vaccines: ready for prime time?

Since the discovery, over a decade and a half ago, that genetically engineered DNA can be delivered in vaccine form and elicit an immune response, there has been much progress in understanding the basic biology of this platform. A large amount of data has been generated in preclinical model systems, and more sustained cellular responses and more consistent antibody responses are being observed in the clinic. Four DNA vaccine products have recently been approved, all in the area of veterinary medicine. These results suggest a productive future for this technology as more optimized constructs, better trial designs and improved platforms are being brought into the clinic.

[1]  R. Steinman,et al.  The efficacy of DNA vaccination is enhanced in mice by targeting the encoded protein to dendritic cells. , 2008, The Journal of clinical investigation.

[2]  L. Babiuk,et al.  A single HBsAg DNA vaccination in combination with electroporation elicits long-term antibody responses in sheep. , 2007, Bioelectrochemistry.

[3]  Feng Gao,et al.  Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins. , 2007, Virology.

[4]  Anne S De Groot,et al.  HIV vaccine development by computer assisted design: the GAIA vaccine. , 2005, Vaccine.

[5]  D. Weiner,et al.  Safety and immunogenicity of intramuscular and intravaginal delivery of HIV‐1 DNA constructs to infant chimpanzees , 1997, Journal of medical primatology.

[6]  P. Chambon,et al.  The SV40 72 base repair repeat has a striking effect on gene expression both in SV40 and other chimeric recombinants. , 1981, Nucleic acids research.

[7]  S. Hoffman,et al.  Safety, tolerability, and lack of antibody responses after administration of a PfCSP DNA malaria vaccine via needle or needle-free jet injection, and comparison of intramuscular and combination intramuscular/intradermal routes. , 2002, Human gene therapy.

[8]  S. Govindarajan,et al.  Codon bias and heterologous protein expression. , 2004, Trends in biotechnology.

[9]  K. Berndt,et al.  Codon optimization reveals critical factors for high level expression of two rare codon genes in Escherichia coli: RNA stability and secondary structure but not tRNA abundance. , 2004, Biochemical and biophysical research communications.

[10]  Jagdish Singh,et al.  Skin targeted DNA vaccine delivery using electroporation in rabbits II. Safety. , 2006, International journal of pharmaceutics.

[11]  D. Weiner,et al.  Combined effects of IL-12 and electroporation enhances the potency of DNA vaccination in macaques. , 2008, Vaccine.

[12]  Wim E Hennink,et al.  Lipid-coated polyplexes for targeted gene delivery to ovarian carcinoma cells , 2001, Cancer Gene Therapy.

[13]  T. Kurata,et al.  Protection against influenza virus infection in mice immunized by administration of hemagglutinin-expressing DNAs with electroporation. , 2000, Vaccine.

[14]  R. Mumper,et al.  Intradermal immunization with novel plasmid DNA-coated nanoparticles via a needle-free injection device. , 2003, Journal of biotechnology.

[15]  R. Germain,et al.  Predominant Role for Directly Transfected Dendritic Cells in Antigen Presentation to CD8+ T Cells after Gene Gun Immunization , 1998, The Journal of experimental medicine.

[16]  J. Wolchok,et al.  Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center. , 2006, Vaccine.

[17]  Hideki Ito,et al.  Promoter Sequences of Varicella-Zoster Virus Glycoprotein I Targeted by Cellular Transactivating Factors Sp1 and USF Determine Virulence in Skin and T Cells in SCIDhu Mice In Vivo , 2003, Journal of Virology.

[18]  J. Traub-Dargatz,et al.  Immunologic responses to West Nile virus in vaccinated and clinically affected horses. , 2005, Journal of the American Veterinary Medical Association.

[19]  H. Temin.  Overview of biological effects of addition of DNA molecules to cells , 1990, Developments in biological standardization.

[20]  E. Bahraoui,et al.  Comparative study of immune responses induced after immunization with plasmids encoding the HIV-1 Nef protein under the control of the CMV-IE or the muscle-specific desmin promoter. , 2002, Vaccine.

[21]  Mansoor M Amiji,et al.  Polymeric nano- and microparticle technologies for oral gene delivery , 2007, Expert opinion on drug delivery.

[22]  C. Griot,et al.  DNA vaccines: safety aspect assessment and regulation. , 2006, Developments in biologicals.

[23]  D. Webster,et al.  Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans , 2003, Nature Medicine.

[24]  M. Jaroszeski,et al.  In vivo electroporation of plasmids encoding GM-CSF or interleukin-2 into existing B16 melanomas combined with electrochemotherapy induces long-term antitumour immunity , 2000, Melanoma research.

[25]  L. Kwak,et al.  Prophylactic anti-tumor effects in a B cell lymphoma model with DNA vaccines delivered on polyethylenimine (PEI) functionalized PLGA microparticles. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[26]  M. Nakanishi,et al.  Confocal and probe microscopy to study gene transfection mediated by cationic liposomes with a cationic cholesterol derivative. , 2001, Advanced drug delivery reviews.

[27]  Larry R. Smith,et al.  Vaxfectin™-Formulated Influenza DNA Vaccines Encoding NP and M2 Viral Proteins Protect Mice against Lethal Viral Challenge , 2007, Human vaccines.

[28]  M. Ackers,et al.  Generation of a consensus sequence from prevalent and incident HIV-1 infections in West Africa to guide AIDS vaccine development. , 2002, Virology.

[29]  Simon C Watkins,et al.  DNA–based immunization by in vivo transfection of dendritic cells , 1996, Nature Medicine.

[30]  Bin Wang,et al.  Gene inoculation generates immune responses against human immunodeficiency virus type 1. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[31]  J. Hooper,et al.  Smallpox DNA vaccine delivered by novel skin electroporation device protects mice against intranasal poxvirus challenge , 2006, Vaccine.

[32]  T. Yamano,et al.  Enhancement of immunity by a DNA melanoma vaccine against TRP2 with CCL21 as an adjuvant. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[33]  B. Moss,et al.  DNA/MVA vaccine for HIV type 1: effects of codon-optimization and the expression of aggregates or virus-like particles on the immunogenicity of the DNA prime. , 2004, AIDS research and human retroviruses.

[34]  H. Dockrell,et al.  Vaccinia expression of Mycobacterium tuberculosis-secreted proteins: tissue plasminogen activator signal sequence enhances expression and immunogenicity of M. tuberculosis Ag85. , 2000, Microbes and infection.

[35]  M. Tao,et al.  In vivo electroporation of skeletal muscles increases the efficacy of Japanese encephalitis virus DNA vaccine. , 2004, Vaccine.

[36]  J. Rice,et al.  Electroporation as a “Prime/Boost” Strategy for Naked DNA Vaccination against a Tumor Antigen1 , 2005, The Journal of Immunology.

[37]  D. Y. Thomas,et al.  The HIV-1 Env protein signal sequence retards its cleavage and down-regulates the glycoprotein folding. , 2000, Virology.

[38]  W. Eaglstein,et al.  Synergistic Effect of Formulated Plasmid and Needle-Free Injection for Genetic Vaccines , 1999, Pharmaceutical Research.

[39]  R. Grabherr,et al.  A novel antibiotic free plasmid selection system: Advances in safe and efficient DNA therapy , 2008, Biotechnology journal.

[40]  H L Robinson,et al.  DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[41]  E. Griffiths,et al.  Assuring the quality, safety, and efficacy of DNA vaccines , 2001, Molecular biotechnology.

[42]  E. Nabel,et al.  Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[43]  J. Ulmer,et al.  Gene-based vaccines: recent technical and clinical advances. , 2006, Trends in molecular medicine.

[44]  Yingyu Chen,et al.  Preparation and characterization of a monoclonal antibody against CKLF1 using DNA immunization with in vivo electroporation. , 2005, Hybridoma.

[45]  Y. Maa,et al.  Needle-free epidermal powder immunization , 2002, Expert review of vaccines.

[46]  L. Babiuk,et al.  Strategies for improved formulation and delivery of DNA vaccines to veterinary target species , 2004, Immunological reviews.

[47]  J. Lisziewicz,et al.  Induction of HIV-specific memory T-cell responses by topical DermaVir vaccine. , 2007, Vaccine.

[48]  Xiang Gao,et al.  Cationic liposome-mediated gene transfer. , 1995, Gene therapy.

[49]  R. Ruprecht.  Live attenuated AIDS viruses as vaccines: promise or peril? , 1999, Immunological reviews.

[50]  T. Waldmann,et al.  Coimmunization with an Optimized IL-15 Plasmid Results in Enhanced Function and Longevity of CD8 T Cells That Are Partially Independent of CD4 T Cell Help3 , 2005, The Journal of Immunology.

[51]  F. He,et al.  Relative contributions of codon usage, promoter efficiency and leader sequence to the antigen expression and immunogenicity of HIV-1 Env DNA vaccine. , 2006, Vaccine.

[52]  K. Ishii,et al.  DNA vaccines: capacity to induce auto-immunity and tolerance. , 2000, Developments in biologicals.

[53]  S. Hoffman,et al.  Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. , 1998, Science.

[54]  Feng-qian Li,et al.  Strong cellular and humoral immune responses induced by transcutaneous immunization with HBsAg DNA–cationic deformable liposome complex , 2007, Experimental dermatology.

[55]  W. W. Nichols,et al.  Plasmid DNA Vaccines: Investigation of Integration into Host Cellular DNA following Intramuscular Injection in Mice , 2001, Intervirology.

[56]  J. Mascola,et al.  A Human T-Cell Leukemia Virus Type 1 Regulatory Element Enhances the Immunogenicity of Human Immunodeficiency Virus Type 1 DNA Vaccines in Mice and Nonhuman Primates , 2005, Journal of Virology.

[57]  C. González-Bonilla,et al.  A fusogenic peptide expressed on the surface of Salmonella enterica elicits CTL responses to a dengue virus epitope. , 2007, Vaccine.

[58]  D. Tang,et al.  Genetic immunization is a simple method for eliciting an immune response , 1992, Nature.

[59]  Julie Gehl,et al.  Electrochemotherapy: results of cancer treatment using enhanced delivery of bleomycin by electroporation. , 2003, Cancer treatment reviews.

[60]  W. Hennink,et al.  Cationic polymers that enhance the performance of HbsAg DNA in vivo. , 2004, Vaccine.

[61]  G. Gregoriadis,et al.  Liposome-entrapped plasmid DNA: characterisation studies. , 2000, Biochimica et biophysica acta.

[62]  A. McMichael,et al.  Safety and tolerability of recombinant modified vaccinia virus Ankara expressing an HIV-1 gag/multiepitope immunogen (MVA.HIVA) in HIV-1-infected persons receiving combination antiretroviral therapy. , 2007, Vaccine.

[63]  Joshy Jacob,et al.  The Hybrid Cytomegalovirus Enhancer/Chicken β-Actin Promoter along with Woodchuck Hepatitis Virus Posttranscriptional Regulatory Element Enhances the Protective Efficacy of DNA Vaccines1 , 2004, The Journal of Immunology.

[64]  Y. Kaneda,et al.  Protective immunization against melanoma by gp100 DNA–HVJ-liposome vaccine , 1999, Gene Therapy.

[65]  M. Kozak,et al.  Recognition of AUG and alternative initiator codons is augmented by G in position +4 but is not generally affected by the nucleotides in positions +5 and +6 , 1997, The EMBO journal.

[66]  J. Lisziewicz,et al.  HIV-1 prophylactic vaccine comprised of topical DermaVir prime and protein boost elicits cellular immune responses and controls pathogenic R5 SHIV162P3. , 2007, Virology.

[67]  J. Mascola,et al.  Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. , 2006, The Journal of infectious diseases.

[68]  D. Weiner,et al.  Intradermal/subcutaneous immunization by electroporation improves plasmid vaccine delivery and potency in pigs and rhesus macaques. , 2008, Vaccine.

[69]  M. Ramanathan,et al.  Induction of Inflammation by West Nile virus Capsid through the Caspase-9 Apoptotic Pathway , 2002, Emerging infectious diseases.

[70]  B. Wahrén,et al.  Induction of mucosal IgA by a novel jet delivery technique for HIV-1 DNA. , 1999, Vaccine.

[71]  Lei Jiang,et al.  Enhanced immunogenicity of microencapsulated multiepitope DNA vaccine encoding T and B cell epitopes of foot-and-mouth disease virus in mice. , 2006, Vaccine.

[72]  D. Fuller,et al.  Clinical safety and efficacy of a powdered Hepatitis B nucleic acid vaccine delivered to the epidermis by a commercial prototype device. , 2005, Vaccine.

[73]  F. Chang,et al.  Analysis of Humoral Immunity of Hepatitis D Virus DNA Vaccine Generated in Mice by Using Different Dosage, Gene Gun Immunization, and In Vivo Electroporation , 2006, Journal of the Chinese Medical Association : JCMA.

[74]  G. Pantaleo,et al.  Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity. , 2007, Vaccine.

[75]  A. Folgori,et al.  Modulation of the Immune Response Induced by Gene Electrotransfer of a Hepatitis C Virus DNA Vaccine in Nonhuman Primates , 2006, The Journal of Immunology.

[76]  C. Ottensmeier,et al.  DNA fusion gene vaccines against cancer: from the laboratory to the clinic , 2004, Immunological reviews.

[77]  Zhigang Tian,et al.  mRNA secondary structure at start AUG codon is a key limiting factor for human protein expression in Escherichia coli. , 2006, Biochemical and biophysical research communications.

[78]  S. Hoffman,et al.  Codon Optimization of Gene Fragments EncodingPlasmodium falciparum Merzoite Proteins Enhances DNA Vaccine Protein Expression and Immunogenicity in Mice , 2001, Infection and Immunity.

[79]  J. Ulmer,et al.  Potent immunogenicity of an HIV-1 gag-pol fusion DNA vaccine delivered by in vivo electroporation. , 2006, Vaccine.

[80]  H. Merkle,et al.  DNA-loaded biodegradable microparticles as vaccine delivery systems and their interaction with dendritic cells. , 2005, Advanced drug delivery reviews.

[81]  A. Simon,et al.  Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. , 2000, Science.

[82]  D. Carbone,et al.  Puncture-mediated gene transfer to the skin. , 1996, Human gene therapy.

[83]  C. Milstein,et al.  Continuous cultures of fused cells secreting antibody of predefined specificity , 1975, Nature.

[84]  A. Sette,et al.  Design of multi-epitope, analogue-based cancer vaccines , 2003, Expert opinion on biological therapy.

[85]  J. Maguire,et al.  Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers. , 2000, Vaccine.

[86]  S. Mitragotri,et al.  Low-frequency ultrasound as a transcutaneous immunization adjuvant. , 2005, Vaccine.

[87]  A. McMichael,et al.  Development of a DNA-MVA/HIVA vaccine for Kenya. , 2002, Vaccine.

[88]  I. Pastan,et al.  The Rous sarcoma virus long terminal repeat is a strong promoter when introduced into a variety of eukaryotic cells by DNA-mediated transfection. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[89]  D. Weiner,et al.  Immunogenicity of novel consensus-based DNA vaccines against avian influenza. , 2007, Vaccine.

[90]  C. Ockenhouse,et al.  Effect of Codon Optimization on Expression Levels of a Functionally Folded Malaria Vaccine Candidate in Prokaryotic and Eukaryotic Expression Systems , 2003, Infection and Immunity.

[91]  Y. Cheung,et al.  Plasmid encoding papillomavirus Type 16 (HPV16) DNA constructed with codon optimization improved the immunogenicity against HPV infection. , 2004, Vaccine.

[92]  W. W. Nichols,et al.  Plasmid DNA Vaccines: Tissue Distribution and Effects of DNA Sequence, Adjuvants and Delivery Method on Integration into Host DNA , 2001, Intervirology.

[93]  V. Apostolopoulos,et al.  Poly-L-lysine-coated nanoparticles: a potent delivery system to enhance DNA vaccine efficacy. , 2007, Vaccine.

[94]  P. Minor.  Regulatory Issues in the Use of DNA Vaccines , 1995, Annals of the New York Academy of Sciences.

[95]  Alessandra Conversi,et al.  Comparative Analysis , 2009, Encyclopedia of Database Systems.

[96]  W. W. Nichols,et al.  Potential DNA Vaccine Integration into Host Cell Genome , 1995, Annals of the New York Academy of Sciences.

[97]  K. M. Mohankumar,et al.  Codon Optimization of the Tat Antigen of Human Immunodeficiency Virus Type 1 Generates Strong Immune Responses in Mice following Genetic Immunization , 2004, Journal of Virology.

[98]  E. Thacker,et al.  Plasmid-mediated growth hormone-releasing hormone efficacy in reducing disease associated with Mycoplasma hyopneumoniae and porcine reproductive and respiratory syndrome virus infection. , 2006, Journal of animal science.

[99]  P. Offit.  The Cutter incident, 50 years later. , 2005, The New England journal of medicine.

[100]  Guidance for Industry Considerations for Plasmid DNA Vaccines for Infectious Disease Indications Contains Nonbinding Recommendations Draft-Not for Implementation , 2005 .

[101]  Robert Langer,et al.  A polymer library approach to suicide gene therapy for cancer. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[102]  C. Tacket,et al.  Phase 1 safety and immune response studies of a DNA vaccine encoding hepatitis B surface antigen delivered by a gene delivery device. , 1999, Vaccine.

[103]  J. Prieto,et al.  Induction of gp120-specific protective immune responses by genetic vaccination with linear polyethylenimine-plasmid complex. , 2005, Vaccine.

[104]  N. Sardesai,et al.  Heterosubtypic Protection against Pathogenic Human and Avian Influenza Viruses via In Vivo Electroporation of Synthetic Consensus DNA Antigens , 2008, PloS one.

[105]  Yuhong Xu,et al.  Electric pulses applied prior to intramuscular DNA vaccination greatly improve the vaccine immunogenicity. , 2007, Vaccine.

[106]  H. Herweijer,et al.  High expression of naked plasmid DNA in muscles of young rodents. , 1997, Human molecular genetics.

[107]  J. Ulmer,et al.  Human clinical trials of plasmid DNA vaccines. , 2005, Advances in genetics.

[108]  O. Weiland,et al.  Codon optimization and mRNA amplification effectively enhances the immunogenicity of the hepatitis C virus nonstructural 3/4A gene , 2004, Gene Therapy.

[109]  B. Livingston,et al.  Immunostimulatory DNA as a vaccine adjuvant , 2007, Expert review of vaccines.

[110]  John Sidney,et al.  A Rational Strategy to Design Multiepitope Immunogens Based on Multiple Th Lymphocyte Epitopes1 , 2002, The Journal of Immunology.

[111]  H. Greenberg,et al.  Immune responses and protection obtained by oral immunization with rotavirus VP4 and VP7 DNA vaccines encapsulated in microparticles. , 1999, Virology.

[112]  C. Botev,et al.  Naked DNA and Adenoviral Immunizations for Immunotherapy of Prostate Cancer: A Phase I/II Clinical Trial , 2000, European Urology.

[113]  D. Sherratt,et al.  Escherichia coli strains that allow antibiotic-free plasmid selection and maintenance by repressor titration. , 2001, Nucleic acids research.

[114]  Henryk Mach,et al.  Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity , 2002, Nature.

[115]  D. Doolan,et al.  Enhancement of antibody and cellular immune responses to malaria DNA vaccines by in vivo electroporation. , 2007, Vaccine.

[116]  M. E. Christopher,et al.  Intranasal immunization with liposome-encapsulated plasmid DNA encoding influenza virus hemagglutinin elicits mucosal, cellular and humoral immune responses. , 2004, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[117]  R. F. Cook,et al.  Multiple RNA splicing and the presence of cryptic RNA splice donor and acceptor sites may contribute to low expression levels and poor immunogenicity of potential DNA vaccines containing the env gene of equine infectious anemia virus (EIAV). , 2002, Veterinary microbiology.

[118]  S. Xiong,et al.  DNA electroporation prime and protein boost strategy enhances humoral immunity of tuberculosis DNA vaccines in mice and non-human primates. , 2006, Vaccine.

[119]  R. Kurth.  Risk Potential of the Chromosomal Insertion of Foreign DNA , 1995, Developments in biological standardization.

[120]  Piero Musiani,et al.  Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice. , 2004, Cancer research.

[121]  R. Webster,et al.  DNA vaccines. , 1996, AIDS research and human retroviruses.

[122]  T. Mayumi,et al.  Optimization of transcriptional regulatory elements for constructing plasmid vectors. , 2001, Gene.

[123]  K. Garver,et al.  Efficacy of an infectious hematopoietic necrosis (IHN) virus DNA vaccine in Chinook Oncorhynchus tshawytscha and sockeye O. nerka salmon. , 2005, Diseases of aquatic organisms.

[124]  J. Ulmer,et al.  Microparticle-based technologies for vaccines. , 2006, Methods.

[125]  H. Rockette,et al.  From the laboratory to the clinic: the "prevalence effect". , 2003, Academic radiology.

[126]  C. Ottensmeier,et al.  DNA vaccines: precision tools for activating effective immunity against cancer , 2008, Nature Reviews Cancer.

[127]  L. Stamatatos,et al.  Prospects of HIV Env modification as an approach to HIV vaccine design. , 2007, Current HIV research.

[128]  Rupinderjeet Kaur,et al.  Immunogenicity in mice of a cationic microparticle-adsorbed plasmid DNA encoding Japanese encephalitis virus envelope protein. , 2004, Vaccine.

[129]  K. Barnhart,et al.  An improved plasmid DNA expression vector for direct injection into skeletal muscle. , 1996, Human gene therapy.

[130]  A. Sette,et al.  Recognition of Variant HIV-1 Epitopes from Diverse Viral Subtypes by Vaccine-Induced CTL1 , 2004, The Journal of Immunology.

[131]  W. W. Nichols,et al.  Plasmid DNA vaccines: assay for integration into host genomic DNA. , 2000, Developments in biologicals.

[132]  A. Ludwig,et al.  Microneedles for transdermal drug delivery: a minireview. , 2008, Frontiers in bioscience : a journal and virtual library.

[133]  M. Ramanathan,et al.  Enhanced cellular immune responses elicited by an engineered HIV-1 subtype B consensus-based envelope DNA vaccine. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[134]  C. Andrews,et al.  Biodistribution of DNA Plasmid Vaccines against HIV-1, Ebola, Severe Acute Respiratory Syndrome, or West Nile Virus Is Similar, without Integration, despite Differing Plasmid Backbones or Gene Inserts , 2006, Toxicological sciences : an official journal of the Society of Toxicology.

[135]  Deborah H Fuller,et al.  Preclinical and clinical progress of particle-mediated DNA vaccines for infectious diseases. , 2006, Methods.

[136]  Piero Musiani,et al.  Cure of Mammary Carcinomas in Her-2 Transgenic Mice through Sequential Stimulation of Innate (Neoadjuvant Interleukin-12) and Adaptive (DNA Vaccine Electroporation) Immunity , 2005, Clinical Cancer Research.

[137]  J. Mascola,et al.  Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. , 2006, The Journal of infectious diseases.

[138]  N. Letvin,et al.  Codon usage optimization of HIV type 1 subtype C gag, pol, env, and nef genes: in vitro expression and immune responses in DNA-vaccinated mice. , 2003, AIDS research and human retroviruses.

[139]  Michael Boshart,et al.  A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus , 1985, Cell.

[140]  T. Nutman,et al.  Novel Phage Display-Based Subtractive Screening To Identify Vaccine Candidates of Brugia malayi , 2004, Infection and Immunity.

[141]  Jonathan M Gershoni,et al.  Computational prediction of the cross‐reactive neutralizing epitope corresponding to the monoclonal antibody b12 specific for HIV‐1 gp120 , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[142]  D. Weiner,et al.  Safety and immune responses to a DNA-based human immunodeficiency virus (HIV) type I env/rev vaccine in HIV-infected recipients: follow-up data. , 2000, The Journal of infectious diseases.

[143]  Jagdish Singh,et al.  Skin targeted DNA vaccine delivery using electroporation in rabbits. I: efficacy. , 2005, International journal of pharmaceutics.

[144]  E. Konishi,et al.  Needle-free jet injection of a mixture of Japanese encephalitis DNA and protein vaccines: a strategy to effectively enhance immunogenicity of the DNA vaccine in a murine model. , 2005, Viral immunology.

[145]  Shixia Wang,et al.  Definitive toxicology and biodistribution study of a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 (HIV-1) vaccine in rabbits. , 2006, Vaccine.

[146]  D. Montefiori,et al.  Effect of Plasmid DNA Vaccine Design and In Vivo Electroporation on the Resulting Vaccine-Specific Immune Responses in Rhesus Macaques , 2007, Journal of Virology.

[147]  Y. Liu,et al.  Enhancement of DNA vaccine‐induced immune responses by a 72‐bp element from SV40 enhancer , 2007, Chinese medical journal.

[148]  J. Shiver,et al.  Heterologous and homologous protection against influenza A by DNA vaccination: optimization of DNA vectors. , 1993, DNA and cell biology.

[149]  J. Reimann,et al.  Efficient vaccination by intradermal or intramuscular inoculation of plasmid DNA expressing hepatitis B surface antigen under desmin promoter/enhancer control. , 2000, Vaccine.

[150]  N. Ishii,et al.  Topical application of HIV DNA vaccine with cytokine-expression plasmids induces strong antigen-specific immune responses. , 2001, Vaccine.

[151]  L. Babiuk,et al.  Delivery of DNA vaccines using electroporation. , 2006, Methods in molecular medicine.

[152]  Z. Weng,et al.  Ancestral and consensus envelope immunogens for HIV-1 subtype C. , 2006, Virology.

[153]  W. Mcclements,et al.  Immunization of non-human primates with DNA vaccines. , 1997, Vaccine.

[154]  A. Nicolini,et al.  Electrochemotherapy a novel approach to the treatment of metastatic nodules on the skin and subcutaneous tissues. , 2006, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[155]  M. Ustav,et al.  Cross-clade protection induced by human immunodeficiency virus-1 DNA immunogens expressing consensus sequences of multiple genes and epitopes from subtypes A, B, C, and FGH. , 2005, Viral immunology.

[156]  M. Ramanathan,et al.  Immunogenicity testing of a novel engineered HIV-1 envelope gp140 DNA vaccine construct. , 2006, DNA and cell biology.

[157]  J. Bramson,et al.  The efficacy of electroporated plasmid vaccines correlates with long-term antigen production in vivo. , 2004, Vaccine.

[158]  D. Montefiori,et al.  Enhanced Potency of Plasmid DNA Microparticle Human Immunodeficiency Virus Vaccines in Rhesus Macaques by Using a Priming-Boosting Regimen with Recombinant Proteins , 2005, Journal of Virology.

[159]  E. Williamson,et al.  Antibiotic-Free Plasmid Stabilization by Operator-Repressor Titration for Vaccine Delivery by Using Live Salmonella enterica Serovar Typhimurium , 2005, Infection and Immunity.

[160]  P. Pisa,et al.  Enhancement of cellular immune response to a prostate cancer DNA vaccine by intradermal electroporation. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[161]  J. Ulmer,et al.  Heterologous protection against influenza by injection of DNA encoding a viral protein. , 1993, Science.

[162]  D. Weiner,et al.  First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. , 1998, The Journal of infectious diseases.